Fibulin-3 Biomarker Becomes Latest Breakthrough in Mesothelioma Research

Research & Clinical Trials
Reading Time: 3 mins
Publication Date: 10/22/2012
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Lashawn
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite Asbestos.com’s Article

APA

Povtak, T. (2022, January 25). Fibulin-3 Biomarker Becomes Latest Breakthrough in Mesothelioma Research. Asbestos.com. Retrieved January 30, 2023, from https://www.asbestos.com/news/2012/10/22/fibulin-3-biomarker/

MLA

Povtak, Tim. "Fibulin-3 Biomarker Becomes Latest Breakthrough in Mesothelioma Research." Asbestos.com, 25 Jan 2022, https://www.asbestos.com/news/2012/10/22/fibulin-3-biomarker/.

Chicago

Povtak, Tim. "Fibulin-3 Biomarker Becomes Latest Breakthrough in Mesothelioma Research." Asbestos.com. Last modified January 25, 2022. https://www.asbestos.com/news/2012/10/22/fibulin-3-biomarker/.

The search to uncover easier and earlier ways to diagnose mesothelioma took a step in the right direction with the latest findings from the laboratory of New York University Langone Medical Center and renowned thoracic oncologist Harvey Pass, M.D.

Researchers there have found that fibulin-3 a new protein biomarker found in blood can reliably predict the presence, or absence, of mesothelioma cancer cells. This finding could open the way for a long sought-after screening tool for anyone exposed to asbestos.

“There is reason to be encouraged,” Pass said in recent interview with Asbestos.com. “Stay tuned. There is a real interest in this research because the real gain will be made by finding it (mesothelioma) earlier, when the treatments can be more effective.”

The findings were published this month in the New England Journal of Medicine. Pass was joined in the study by high-profile colleagues Michele Carbone, M.D., the University of Hawaii Cancer Center;  Michael Harbut, M.D., Wayne State University; and Anne Tsao, M.D., the MD Anderson Cancer Center in Houston.

Mesothelioma is a rare cancer caused by asbestos exposure. It is diagnosed in an estimated 3,000 Americans each year, leaving many with a grim prognosis.  By the time mesothelioma usually is diagnosed, surgery often is not an option because the cancer already has spread throughout the body.

The medical community in the past has struggled in its search for a reliable screening tool. Because mesothelioma symptoms often can mirror those of less serious illnesses, an accurate diagnosis can be a six-month process.

This latest discovery could be a significant breakthrough, allowing doctors to accelerate the process and possibly monitor the presence of fibulin-3 in people with a history of major exposure to asbestos.

“It’s a first step, but a very promising step,” Pass told Reuters Health. “We’re enthused that this marker eventually will help the mesothelioma community.”

This study had a 96.7 percent success rate in accurately determining the presence or absence of mesothelioma when looking at blood and pleural fluid of patients.

The study included the measuring of fibulin-3 levels in 92 people with mesothelioma, 136 cancer-free patients with previous asbestos exposure, 93 with pleural effusions unrelated to mesothelioma, and 43 health controls.

Pass believes the next step toward advancement will be monitoring a larger group of high-risk patients to see if their fibulin-3 levels begin to elevate and reflect early stage mesothelioma.

“The problem now is that patients present with late-stage, bulky disease where we have very few options,” Pass told Reuters Health. “With an earlier presentation, you have a surgical option and better treatment results, and they have better responses to chemotherapy. You can convert this to a disease that you can chronically treat.”

The best treatment results currently have come from a multimodal approach that includes surgery, chemotherapy and radiation. With that approach, early stage patients often can live more than two years, and a few from five to 10 years after the initial diagnosis.

Scientists have been looking at various biomarkers for several years, but none have been as reliable as fibulin-3 was in this latest report. The protein mesothelin often has been cited as a biomarker for mesothelioma, but it has not shown the sensitivity to testing that fibulin-3 has. It is considered unreliable for early stage testing.

Earlier this year, Pass received the Pioneer Award from the Mesothelioma Applied Research Foundation for his research work. His latest findings are expected to be greeted enthusiastically in the mesothelioma community.

Connect with a Mesothelioma Doctor
Find a Top Specialist Near You